Q4 2025 EPS Estimates for Ashland Inc. (NYSE:ASH) Increased by Analyst

Ashland Inc. (NYSE:ASH) – Seaport Res Ptn raised their Q4 2025 earnings per share estimates for Ashland in a research note issued on Monday, May 6th. Seaport Res Ptn analyst M. Harrison now expects that the basic materials company will post earnings per share of $1.74 for the quarter, up from their prior estimate of $1.73. The consensus estimate for Ashland’s current full-year earnings is $4.47 per share.

Several other equities analysts also recently issued reports on ASH. Mizuho boosted their price objective on Ashland from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. StockNews.com raised Ashland from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. TheStreet raised Ashland from a “c+” rating to a “b-” rating in a report on Thursday, February 22nd. BMO Capital Markets upped their price objective on shares of Ashland from $97.00 to $105.00 and gave the stock a “market perform” rating in a report on Tuesday. Finally, Wells Fargo & Company raised shares of Ashland from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $100.00 to $112.00 in a research note on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.44.

Ashland Trading Down 0.5 %

NYSE:ASH opened at $97.57 on Thursday. The firm has a market capitalization of $4.89 billion, a P/E ratio of 25.88 and a beta of 0.92. The business has a 50 day simple moving average of $95.87 and a 200 day simple moving average of $87.36. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.15 and a quick ratio of 1.94. Ashland has a 12-month low of $70.82 and a 12-month high of $99.55.

Ashland (NYSE:ASH) last issued its earnings results on Wednesday, May 1st. The basic materials company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.13. The firm had revenue of $575.00 million for the quarter, compared to analysts’ expectations of $574.64 million. Ashland had a net margin of 9.09% and a return on equity of 5.57%. Ashland’s revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the company posted $1.43 earnings per share.

Hedge Funds Weigh In On Ashland

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Ashland by 122.4% in the 1st quarter. GAMMA Investing LLC now owns 278 shares of the basic materials company’s stock valued at $27,000 after buying an additional 153 shares during the last quarter. Global Retirement Partners LLC bought a new position in Ashland during the fourth quarter worth $28,000. Hexagon Capital Partners LLC raised its stake in Ashland by 143.9% during the 4th quarter. Hexagon Capital Partners LLC now owns 378 shares of the basic materials company’s stock valued at $32,000 after purchasing an additional 223 shares during the last quarter. Covestor Ltd increased its holdings in shares of Ashland by 338.0% during the 3rd quarter. Covestor Ltd now owns 403 shares of the basic materials company’s stock worth $33,000 after purchasing an additional 311 shares during the period. Finally, Allworth Financial LP lifted its stake in shares of Ashland by 43.1% in the third quarter. Allworth Financial LP now owns 561 shares of the basic materials company’s stock valued at $46,000 after buying an additional 169 shares during the period. Institutional investors own 93.95% of the company’s stock.

About Ashland

Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.